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Angiotensin II type I receptorMutant forms of kinin B1 receptor (B1R) and analogs of the full agonist des-Arg9-bradykinin (DABK) were in-
vestigated aiming to verify the importance of selected receptor residues and of each agonist-peptide residue
in the speciﬁc binding and activation. Linked by a speciﬁc disulﬁde bond (Cys100–Cys650), the N-terminal (Nt)
and the EC3 loop C-terminal (Ct) segments of angiotensin II (AngII) receptor 1 (AT1R) have been identiﬁed to
form an extracellular site for binding the agonist Nt segment (Asp1 and Arg2 residues). Asp712 residue at the
receptor EC3 loop binds the peptide Arg2 residue. By homology, a similar site might be considered for DABK
binding to B1R since this receptor contains the same structural elements for composing the site in AT1R,
namely the disulﬁde bond and the EC3 loop Asp712 residue. DABK, Alan-DABK analogs (n=Ala1-, Ala2-,
Ala3-, Ala4-, Ala5-, Ala6-, Ala7-, Ala8-DABK), and other analogs were selected to binding wild-type, Asp712Ala
and Cys100Ser mutated B1R receptors. The results obtained suggested that the same bimodal scheme
adopted for AngII-AT1R system may be applied to DABK binding to B1R. The most crucial similarity in the
two cases is that the Nt segments of peptides equally bind to the homologous Asp712 residue of both AT1R
and B1R extracellular sites. Conﬁrming this preliminary supposition, mutation of residues located at the
B1R extracellular site as EC3 loop Asp
712 and Cys100 caused the same modiﬁcations in biological assays ob-
served in AT1R submitted to homologous mutations, such as signiﬁcant weakening of agonist binding and re-
duction of post-receptor-activation processes. These ﬁndings provided enough support for deﬁning a site that
determines the speciﬁc binding of DABK to B1R receptors.
© 2013 Elsevier B V. . Open access under the Elsevier OA license.1. Introduction
Des-Arg9-bradykinin (DABK)2 is the regular agonist of kinin B1
receptor (B1R), a member of family A G-protein-coupled receptors
(AGPCRs) [1]. As the structure of all these receptors, B1R consists of
a seven transmembrane-helix bundle (7TM), linked to extracellular
N-terminal (Nt) and cytosolic C-terminal (Ct) segments, with the
seven helices alternately connected by three extracellular (EC) and
three cytosolic (IC) loops [2].
At the present time, as most of the AGPCR sequences are known,
a conserved motif has been recognized in all types of angiotensin II
(AngII), bradykinin (BK), endothelin, chemokine, purine and Cys-
leukotriene receptors and some types of neuropeptide receptors,
consisting of an insertion of 8–10 residues in the middle of EC3
loop, including a conserved residue of Cys650 supposedly making a di-
sulﬁde bond with a second conserved Cys100 residue located at the Nt
segment (Figs. 1 and 2), [3]. This pattern was then investigated forpositions, respectively; num-
B [1].
vier OA license.function, especially in AT1R receptors, thus revealing that the AngII
N-terminal segment (Asp1 and Arg2 residues) binds to receptor EC3
loop and Nt segment residues [4–8] leading the conserved motif to
be classiﬁed as an extracellular sub-site for agonist binding [9].
Regarding B1R receptors, binding patterns of DABK seem to be sim-
ilar to those observed in AngII interactionwith AT1R. (1) The agonist Ct
carboxylate group is stabilized by electrostatic contacts with helix III
Lys323 [10] and helix V Arg508 [11] both at the external half of the re-
ceptor 7TM central cavity. (2) The residues in the external segment
of the kinin receptors' helix VI appear to be linked to high-afﬁnity
binding [10]. (3) The agonist N-terminal R1 residue binds to receptor
residues located at the other side of the 7TM structure as EC3 loop
Asp712 (and Glu709) [12]. The homology of binding between B1R and
AT1R is assumed because Asp712 residue of the former receptor corre-
sponds to the Asp712 residue of AT1R extracellular site at which the
AngII Arg2 residue is supposed to bind [6].
In the currentwork, B1R andDABK or analogs are studied aiming to
ascertain the importance of some receptor residues and each agonist
residue for speciﬁc binding, production of IP3 or increase of the cyto-
solic calcium levels. Particularly, effects due to modiﬁcations of the
B1R extracellular site weremonitored by analyzing the binding depen-
dence on the Nt Arg1 residue of DABK. Studies with this approach have
been previously carried out with AT1R leading to the discovery that
Fig. 1. Alignment of angiotensin II type I (AT1R), kinin B1 (B1R) and chemokine (CXC4R) receptors. The residue positions were numbered according to GPCRDB system. Segments
of sequences belonging to a same secondary structure (alpha-helix or beta structure) have a referential 3-digit number: the ﬁrst digit designates the number of helix (1–8 for helices
I–VIII) and other intermediate secondary structures; the second and third digits form a number that deﬁnes a certain position in the respective segment. Thus, different positions
are numbered according to the segments at which they are located and the distance from the respective referentials.
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Cys650) abolishes the Arg2-dependent binding of AngII to the receptor
extracellular site [3,7]. As AngII, DABK also displays an Arg residue at
its Nt segment and thus it might be postulated that B1R extracellularFig. 2. Structure of G-protein-coupled receptors with seven transmembrane-helix bun-
dle. Overview of the structure showing the receptor seven transmembrane-helix bun-
dle in dark blue (only helix IV is not identiﬁed) and the very conserved Cys315–Cys470
disulﬁde bond in gold. The receptor extracellular site is shown in the top of the ﬁgure
consisting of N-terminal and EC3 segments (light blue), the Cys650–Cys100 disulﬁde
bond (gold) and the residue insertion (green). The peptide inserted into a postulated
binding site is shown in magenta.)site could play the same role observed with AT1R, upon binding its
speciﬁc agonist. Herein this possibility was conﬁrmed from experi-
mental results obtained by binding DABK and analogs to Asp712Ala
and Cys100Ser mutants' forms of B1R.
2. Material and methods
2.1. Peptides synthesis
The peptides were synthesized manually in accordance with
the standard tert-butyloxycarbonil (Boc) protocol [13,14]. In the Boc
chemistry, after coupling the Ct amino acid to the resin, the successive
α-amino group deprotection and neutralization steps were performed
in 30% TFA (triﬂuoroacetic acid)/DCM (dichloromethane) (30 min) and
10% TEA (triethylamine)/DCM (10 min). The amino acids were coupled
with 3-fold excess, using DIC (N,N′-diisopropylcarbodiimide)/HOBt
(1-hydroxybenzotriazole) in DMF (N,N-dimethylformamide). After
a 3 h coupling period, the qualitative ninhydrin test was performed to
estimate the completeness of the reaction. To check the purity of the syn-
thesized peptide sequence attached to the resin, cleavage reactions with
small aliquots of resin were carried out in anhydrous HF, at 0 °C for 2 h.
Analytical HPLC (High performance liquid chromatography), as well as
LC/ESI-M (Liquid chromatography/Electrospray ionization -mass spec-
trometry) and amino acid analysis were used to check the homogeneity
of each synthesized resin-bound peptide sequence. The synthesized an-
alogs are presented in Table 1.
2.2. Biological activities of the peptides
Experiments were carried out with C57BL/6J mice from the Centro de
Desenvolvimento de Modelos Experimentais da Universidade Federal de
São Paulo (CEDEME-UNIFESP). The animals were maintained on stan-
dard mouse chow at 21–23 °C and kept on 12 h light:12 h dark cycle
and allowed ad libitum access to food and water. After 12–16 weeks,
old mice weighing 26–30 g were sacriﬁced by cervical dislocation and
exsanguination. This study was in accordance with current guidelines
for the care of laboratory animals and ethical guidelines for investiga-
tions approved by the Animal Care Committee of UNIFESP.
All experiments to assess the biological activities of the new pep-
tides were performed in the mouse stomach, which contains func-
tional B2 and B1 receptors. The stomach fundus isolated from mouse
has been reported to respond to the agonists BK and DABK [15,16]
Table 1
The natural agonist is the des-Arg9-BK (DABK) (compound 2); DABK analogs (1 and
3–12).
Compound Analog Sequence
1 DABK R1 P2 P3 G4 F5 S6 P7 F8
2 A1-DABK A1 P2 P3 G4 F5 S6 P7 F8
3 A2-DABK R1 A2 P3 G4 F5 S6 P7 F8
4 A3-DABK R1 P2 A3 G4 F5 S6 P7 F8
5 A4-DABK R1 P2 P3 A4 F5 S6 P7 F8
6 A5-DABK R1 P2 P3 G4 A5 S6 P7 F8
7 A6-DABK R1 P2 P3 G4 F5 A6 P7 F8
8 A7-DABK R1 P2 P3 G4 F5 S6 A7 F8
9 A8-DABK R1 P2 P3 G4 F5 S6 P7 A8
10 K0-DABK K0 R1 P2 P3 G4 F5 S6 P7 F8
11 K1-DABK K1 P2 P3 G4 F5 S6 P7 F8
12 L4-DABK R1 P2 P3 L4 F5 S6 P7 F8
Peptide amino acids are expressed by the one-letter code. A=alanine, R=arginine, P=
proline, G=glycine, F=phenylalanine, S=serine, K=lysine.
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described by [17] in this tissue.
Stomach fundus was isolated from mouse, divided in two strips of
the longitudinal muscle and mounted into a 5 ml organ baths (Panlab
s.l., Cornella, CA, Spain), containing modiﬁed Krebs-Ringer solution:
144 mM NaCl, 5 mM KCl, 1.1 mM MgSO4, 25 mM NaHCO3, 1.1 mM
NaH2PO4, 1.25 mM CaCl and 5.5 mM glucose at 37 °C (pH 7.4) con-
tinuously carboxygenated (95% O2/5% CO2). Contractile responses
to the stimulations with DABK and its analogs were recorded. The
resting tension was maintained at 0.5 g and the tissues were left to
equilibrate for 90 min, with frequent changing of fresh bathing solu-
tion. Following, changes in tension produced by the stimulants were
measured with a tension transducer TRI201 (Panlab s.l., Cornella, CA,
Spain), through an ampliﬁer Powerlab 4/30 and software Labchart
Pro V7 (ADInstruments, Colorado Springs, CO, USA).
Cumulative concentration-contractile response curves were con-
structed for DABK and analogs, by applying increasing concentrations
(0.1 nM to 1 μM) of each agonist to determine the apparent afﬁnity of
agonists in terms of pD2 (the negative logarithm of the concentration
of agonist that produces 50% of themaximal effect, EC50) and themax-
imal effect (Emax) was calculated in relation to the effect of 140 mM
KCl, which was considered 100%. The curve-ﬁtting analysis for dose-
response curves was performed using the GraphPad-Prism 3.0 Pro-
gram (GraphPad Software, San Diego, CA, US).
2.2.1. Construction of kinin B1R mutants
The vector pEYFP-N1B1R (Clontech Laboratories,Mountain View, CA,
US) expressing rat B1Rwas gently donated by Santos et al. [11] and used
as a template for the mutant Asp712Ala, replacing the Asp712 with Ala
and Cys100Ser, replacing the Cys100 with Ser. The site-directed muta-
genesis was performed with QuickChange site-directed mutagenesis
kit (Stratagene, Santa Clara, CA, US) according to themanufacturer's in-
structions. The mutagenesis oligonucleotides used are listed below. For
a single Asp712Ala mutant (sense, 5′-GAAGGAGATCACAGCCCTGGGCC
TGCAGC-3′ and antisense, 5′-GCTGCAGGCCCAGGGCTGTGATCTCCTTC-
3′). Cys100Ser mutant (sense, 5′-GCCAACATTACCTCCAGCGAGAGTGC
CCTA-3′ and antisense, 5′-TAGGGCACTCTCGCTGGAGGTAATGTTGGC-
3′). All receptor constructs were initially identiﬁed by the presence of
a diagnostic restriction site and subsequently veriﬁed by sequencing.
2.3. Cell culture and transfection
Chinese hamster ovary (CHO) cells were cultured in Dulbecco's
modiﬁed Eagle's medium — DMEM (Invitrogen, Carlsbad, CA, US)
supplemented with 10% of fetal bovine serum, 100 U/ml penicillin,
100 μg/ml streptomycin and 2 mM glutamine (all from Invitrogen,
Carlsbad, CA, US). Cultures were maintained at 37 °C in a humidiﬁed5% CO2 atm. Expression plasmids containing wild-type receptor and
B1R mutated receptors, Asp712Ala and Cys100Ser, were permanently
transfected into CHO cells by lipofectamine 2000 (Invitrogen, Carlsbad,
CA, US), method according to the manufacturer's instructions and
2 μg of plasmid DNA for each sample. For the establishment of stable
cell lines, transfected cultures were maintained in culture medium
supplemented with 750 μg of G-418 (Invitrogen, Carlsbad, CA, US).
2.4. Expression of kinin B1R and mutants in transfected CHO cells
Clones with high expression levels of wild-type B1R mRNA and
of mutated receptors were selected by real-time PCR. CHO cells
transfected with the wild-type receptor and mutants were seeded
at 1×106 cells per well in 6-well plates and left for 24 h at 37 °C.
The culture medium was siphoned off and the total RNA was isolated
using TRIzol® reagent (Invitrogen, Carlsbad, CA, US), according to the
manufacturer's instructions. After puriﬁcation, the presence of intact
RNA was veriﬁed on an ethidium bromide-stained agarose gel and the
total RNA was submitted to reverse transcription using SuperScript™
III First-Strand reverse transcriptase kit (Invitrogen, Carlsbad, CA, US).
To determine the expression of B1R, real-time PCR was performed
with 5 μl of 1:10 dilution cDNA samples pre-obtained, where each reac-
tion was carried out using Taqman Universal PCR Master Mix (Applied
Biosystems, Foster City, CA, US), according to the manufacturer's in-
structions. Primers used for real-time PCR were as follows: murine
β-actin (GenBank accession no. NM007393), forward primer 5′-CTGG
CCTCACTGTCCACCTT-3′ and reverse primer 5′-CGGACTCATCGTACTC
CTGCTT-3′; and probe. 5′-6FAM-CTGATCCACATCTGCT-TAMRA-3′ and
rat B1R (GenBank accession no. NM030851), reverse primer 5′-CAA
ACAGGTTGGCCTTGATGAC-3′, forward primer 5′-CTGGCCCTTCGGAAC
TGA-3′ and probe 5′-6FAM-CCCGCTGACCACCC-TAMRA-3′.
The real-time PCRs were performed with an ABI PRISM® 7000 se-
quence detection system (Applied Biosystems, Foster City, CA, US) and
cycle conditions were: 50 °C for 2 min, 95 °C for 10 min, followed by
50 cycles of 95 °C for 15 s (melting step), 60 °C for 1 min (anneal/
extend step). Increases in the amount of reporter dye ﬂuorescence
during the 50 ampliﬁcation cycles were monitored using Sequence
Detector software (SDS version 1.6, Applied Biosystems, Foster City,
CA, US). Quantiﬁcation of the target amount was performed by mea-
suring the threshold cycle, CT, which is deﬁned as the fractional cycle
number atwhich the ﬂuorescence encounters a ﬁxed threshold. A nor-
malized value to evaluate the mRNA expression was calculated as the
difference in the threshold cycle: the CT values of receptor minus CT
of internal standard (β-actin), resulting in ΔCT. Since it is uncommon
to use ΔCT parameter as a relative expression parameter due to this
logarithmic characteristic, the 2−ΔCT parameter was used to express
the relative gene expression data [18]. B1R mRNA abundance was
quantiﬁed as a relative value compared with an internal reference,
β-actin, of which the abundance was assumed not to change between
the varying experimental conditions.
2.5. Heterologous competition binding assay
The transfected CHO cells were seeded at 5×104 cells per well in
96-well plates and left for 24 h at 37 °C. The culture medium was si-
phoned off and the cells were washed twice with wash buffer (mM—
Tris–HCl 25, MgCl2 5, 0.1% BSA, pH 7.4). Then, theywere suspended in
binding buffer (mM — 25 Tris–HCl, 5 MgCl2, 0.1% BSA and 100 μg/ml
bacitracin, pH 7.4) in the presence of a ﬁxed concentration of the
radioligand. 5×104 cpm/well of des-Arg10[3,4-prolyl-3,4-3H(N)],
(62 Ci/mmol) and different concentrations of the unlabelled ligands
(DABK and analogs, shown in Table 1) for competition binding assays.
The plates were incubated overnight at 4 °C. The binding buffer was
siphoned off and the cells were washed twice with cold wash buffer
and then lysed with lysis buffer (0.5% SDS and 0.1 mol/l NaOH).
Receptor-bound radiolabels were counted to determine inhibition
Table 2
Apparent afﬁnity and maximal effect induced by DABK and analogs on mice stomach
fundus.
Compound Analogs pD2 Emax (% KCl)
1 DABK 8.1±0.3 (7) 59±6 (7)
2 A1-DABK ND ND
3 A2-DABK 7.0±0.3 (5)a 27±2 (5)a
4 A3-DABK 7.1±0.3 (4)a 42±4 (4)a
5 A4-DABK 7.0±0.1 (3)a 53±2 (3)
6 A5-DABK 7.4±0.3 (3)a 55±2 (3)
7 A6-DABK 8.1±0.2 (6) 51±3 (6)
8 A7-DABK 8.0±0.3 (3) 52±6 (3)
9 A8-DABK 7.1±0.3 (3)a 30±1 (3)a
10 K0-DABK 7.5±0.3 (4) 57±4 (4)
11 K1-DABK 8.6±0.2 (4)a 97±8 (4)a
12 L4-DABK ND ND
DABK and DABK analogs-induced isometric contractile responses in mice stomach fun-
dus. The pD2 values (negative logarithm of the agonist concentration (M) that induces
50% of the maximal response) were extracted from the concentration-response sig-
moid logistic curves. The maximal effect (Emax) was calculated in relation to the effect
of 140 mM KCl, which was considered 100%. ND, not determined. Data are means±
S.D. and (n) number of experiments.
a Different from DABK. Pb0.05. DABK=Arg1-Pro2-Pro3-Gly4-Phe5-Ser7-Pro7-Phe8.
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Waltham, MA, US). The binding afﬁnity of ligands for BKR1R and mu-
tants was estimated from inhibition constant (IC50) values obtained
from a nonlinear regression analysis of binding curves of GraphPad
3.0 Program (GraphPad Software, San Diego, CA, US).
2.6. IP3 assay
IP3 production was determined in the transfected CHO cells to test
the functional expression of the wild-type andmutant receptors using
HitHunter Inositol (1,4,5)-trisphosphate [IP3] Assay kit (PerkinElmer,
Waltham, MA, US). The cells were harvested and resuspended in PBS
without CaCl2 and MgCl2 (mM — KCl 2.7, KH2PO4 1.5, NaCl 137 and
Na2HPO4 8) in a concentration of 50,000 cells per μl. In a 96-well
black plate (Perkin-Elmer, Waltham, MA, US), 20 μl of cells per well
was added. Then, those cells were stimulated for 20 s with 10 μl of
increasing concentration of DABK and analogs (0.1 nM to 1 μM) and
quenched with 10 μl perchloric acid 0.2 N (water diluted). The
Tracer-Green and Binding Protein (available in the kit) were incu-
bated in a ﬁnal volume of 20 μl and 40 μl respectively for 5 min in a
plate shaker for each. A standard curve was obtained with increasing
amounts of IP3 (6.7×10−11 to 1.33×10−6 M — available in the kit)
under the same protocol described above. The DABK (100 nM) in-
duced effect was tested in the presence and absence of 1 μM R-715,
a speciﬁc antagonist of B1R, pre-incubated for 30 min. The ﬂuores-
cence polarization was detected by Victor X5 microplate reader
(Perkin-Elmer,Waltham,MA, US). The datawere acquired in triplicate
to draw the dose-response curves using the GraphPad 3.0 Program
(GraphPad Software, San Diego, CA, US).
2.7. Calcium assay
The transfected CHO cells expressing the B1R and the mutants
were seeded at 5×105 cells per well in a 96-well black microplate
with clean bottom (Nunc, Rochester, NY, US) and left for 24 h at
37 °C. The cells were washed with HBSS, pH 7.4 (mM — CaCl2 1.26,
MgCl2–6H2O 0.5, MgSO4–7H2O 0.4, KCl 5.3, KH2PO4 0.4, NaHCO3 4.1,
NaCl 138, Na2HPO4 0.3, D-glucose 5.5, HEPES 20), and thereafter incu-
bated with 100 μl of Fluo-4 non-wash with 2.5 mM of probenecid for
30–45 min in the dark at 37 °C. The ﬂuorescence signal was read in
the Victor X5 microplate reader (Perkin-Elmer, Waltham, MA, US),
and the values obtained from non-stimulated cells were considered
to be the basal Ca2+ level and those obtained from cells stimulated
with increasing concentrations of DABK or analogs (0.1 nM to 1 μM)
were considered as the variations in the [Ca2+]i levels. The calcium
measurements were performed using Fluo4 NW Calcium Assay kit
(Molecular Probes, Eugene, OR, US).
One dose of the peptide was added into each well and the results
were used to draw the sigmoidal dose-response curve. At the end of
each experiment 1 μM ionomycin (a Ca2+ ionophore) was adminis-
tered to expose the cytosolic Fluo-4NW to the free extracellular
Ca2+ to get the maximal ﬂuorescence signal (added Fmax) and 5 mM
of EGTA (ethylene glycol tetraacetic acid) was to chelate all free
Ca2+ in order to get the minimum signal, equivalent to the cell auto-
ﬂuorescence value (Fmin).
The Ca2+ intracellular concentration [Ca2+]i was calculated using
the following formula (Grynkiewicz et al., 1985).
Ca2þ
h i
i
¼ Kd 
F−Fmin
Fmax−F
 
where,
Kd dissociation constant of Fluo-3 equals 450
F the ﬂuorescence signal obtained with 496 nm excitation
and 525 nm emission.Fmin the ﬂuorescence signal obtained in the EGTA presence
(5 mM).
Fmax theﬂuorescence signal obtained in the presence of ionomycin
(1 μM).2.8. Modeling procedure for angiotensin and kinin receptors
Based on sequence alignments of Fig. 1, angiotensin II type I and
kinin B1 receptors were built by homology via the WHAT IF program
[19], to the CXCR4 receptor, the ﬁrst AGPCR possessing sequence fea-
tures resembling the extracellular site, for which a high-resolution 3D
structure has been determined [20].2.9. Statistical analysis
All data are shown as mean±S.D. (n), number of experiments.
Statistical analyses were performed using two-way ANOVA followed
by post-test Bonferroni. For statistical comparison, 95% conﬁdence in-
tervals were used.3. Results
3.1. Biological activity of DABK and analogs
The biological activity of DABK and analogs mediated by B1R
(Table 1) was measured by parameters of apparent afﬁnity (pD2)
and Emax (Table 2) through mechanical recordings of the contractile
responses of stomach fundus isolated from mouse. Afﬁnity was kept
at wild-agonist level by A6-DABK (compound 7); it was slightly in-
creased for K1-DABK (compound 11); it was slightly reduced for
A7-DABK (compound 8) and K0-DABK (compound 10); it was reduced
for A2-, A3-, A4-, A5- and A8-DABK (in order. compounds 3, 4, 5, 6 and
9) and very reduced for A1-, L4-DABK (compounds 2 and 12). Thus,
the crucial positions for binding of DABK were R1, P2, P3, G4, F5 and
F8 being S6 and P7 less important. Lys side-chain at the position 1
can replace Arg; Lys added at the position 0 reduced the binding. At
the position 4, the presence of any residue instead of Gly is deleterious
for binding. Emax values produced by different analogs of DABK varied
from 27% to 97% whereas that value for the control DABK was 59%
(Table 2).
Table 3
Binding afﬁnity of DABK and analogs for wild-type and mutant kinin B1 receptor.
Compound Analogs WT Asp712Ala Cys100Ser
IC50 (nM)
1 DABK 3.1±1.6 (3) 370.5±1.1 (3)b 93.2±1.1 (3)b
2 A1-DABK 152±0.6 (3)a 171.9±1.1 (3)b 108.1±0.1 (3)b
3 A2-DABK 61.5±1.4 (3)a 417±1.1 (3)b 143.2±1.3 (3)b
4 A3-DABK 45.9±1.1 (3)a 507.6±1.0 (3)b 193.5±1.4 (3)b
5 A4-DABK 56.4±1.1 (3)a 639.6±1.0 (3)b 220.6±1.1 (3)b
6 A5-DABK 6.8±1.2 (3)a 384±1.2 (3)b 101.3±1.3 (3)b
7 A6-DABK 2.3±1.1 (3) 216.2±1.0 (3)b 78.9±1.3 (3)b
8 A7-DABK 7.8±1.2 (3)a 144.9±1.1 (3)b 45.9±1.1 (3)b
9 A8-DABK 64.6±1.1 (3)a 797.4±1.0 (3)b 367.8±1.1 (3)b
10 K0-DABK 23.8±1.3 (3)a 133.3±1.1 (3)b 74.6±1.2 (3)b
11 K1-DABK 3.2±1.4 (3) 387.6±1.5 (3)b 55.4±1.4 (3)b
12 L4-DABK 84.8±1.6 (3)a 943.9±1.7 (3)b 109.4±1.5 (3)b
Competition binding afﬁnity was performed using des-Arg10[3,4-prolyl-3,4-3H(N)] and
increasing concentrations of the unlabeled DABK and DABK analogs in cells expressing
WT and kinin B1 receptormutants. Data aremeans±S.D. and (n) number of experiments.
DABK=Arg1-Pro2-Pro3-Gly4-Phe5-Ser7-Pro7-Phe8.
a Different from DABK. Pb0.05.
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CHO cells were permanently transfected with the plasmid
containing the coding region for the wild-type rat B1R and the coding
region for B1R carrying the proposed mutations and with an empty
plasmid (mock cells). The expression of the B1R gene in these cells
was evaluated by real-time PCR, by radioligand binding studies and
by a functional assay on the IP3 production and changes in intracellu-
lar calcium concentration in response to B1R agonist, DABK (Fig. 3).
Fig. 3A shows the mRNA expression of cell clones expressing the B1R
and mutants selected, with high and comparable levels between
them. In the binding study, cells expressing only the B1R receptor
or B1R mutants were able to bind speciﬁcally the B1R agonist with
high afﬁnity, whereas mock cells displayed no binding for the agonist
(Fig. 3B). Furthermore, DABK was able to elicit a concentration-
response effect on the IP3 production in CHO cells expressing the
B1R or mutant receptor but not in mock cells (Fig. 3C). This effect
was inhibited by the speciﬁc B1R antagonist R-715, showing the ex-
pression of a functional membrane receptor (Fig. 3D).b Different from respective peptide from WT receptor. Pb0.05.3.2.1. Parameters for interaction between B1R and DABK or analogs
Data from binding assays, the IC50 value for binding afﬁnity of DABK
analogs to B1R was about 3 nM (Table 3), whereas EC50 for production
of IP3 and increase of cytoplasmic calcium was 6 and 4 nM (Tables 4
and 5) respectively. The dependence of IC50 values for binding afﬁnity,
EC50 for IP3 formation and increase of intracellular calcium, on themod-
iﬁed residues of DABK followed the same pattern observedwith biolog-
ical activity results (Table 2). Also in agreement with biological activityFig. 3. Expression of wild-type and mutant kinin B1 receptors in transfected CHO cells. A, T
receptors and mock cells (expressing the empty plasmid) were quantiﬁed by real-time P
which is obtained by subtracting the CT (threshold cycle) of gene target from the CT of inte
and increasing concentrations of the unlabeled des-Arg9-bradykinin (DABK) in CHO cells ex
percentage of maximum speciﬁc binding of the radioligand. C, IP3 productions were obtaine
mock and kinin B1 receptor mutant. The DABK effect was calculated in relation to the maxi
DABK (100 nM) in CHO cells expressing the wild-type and kinin B1 receptor mutant. DABK
onist of B1R, preincubated for 30 min. Data are means±SD of three experiments *differentresults, Emax values for the three analyses were little impaired being
rather independent of residue modiﬁcations.
The crucial positions for DABK binding were R1, P2, P3, and G4 at
the Nt side segment and at the Ct F8, whereas the intermediate 5–7
positions were less important (Tables 3–5). For instance, the afﬁnity
binding of DABK analogs with Ala at the positions 1–4 and 8 was
low with IC50 values varying from 50 to 150 nM, whereas those ana-
logs with A5-, A6- and A7-DABK had stronger binding with IC50 valueshe mRNA expression values of kinin B1 receptor (WT), Asp712Ala, Cys100Ser mutant
CR. The values of the relative gene expression were calculated as 2−ΔCT parameter,
rnal standard. B, Competition binding proﬁle between des-Arg10[3,4-prolyl-3,4-3H(N)]
pressing the wild-type, mock and kinin B1 receptor mutant. Data are expressed as the
d in response to various concentrations of DABK in CHO cells expressing the wild-type,
mal effect of the peptide. D, Effect of B1R antagonist on the IP3 productions induced by
induced effect was tested in the presence or absence of R-715 (1 μM), a speciﬁc antag-
from WT (Pb0.05).
Table 4
DABK and analogs' induced effect on inositol triphosphate production in wild-type and mutant kinin B1 receptors.
Compound Analogs WT Asp712Ala Cys100Ser
IP3
pD2 Emax pD2 Emax pD2 Emax
1 DABK 8.2±0.1 (3) 30±0.6 (3) 6.4±0.3 (3)b 23±5.3 (3) 7.0±0.3 (3)b 22±2.7 (3)
2 A1-DABK 6.7±0.1 (3)a 23±1.6 (3) 6.4±0.2 (3)b 23±3.7 (3) 6.9±0.1 (3)b 20±0.1 (3)
3 A2-DABK 7.0±0.1 (3)a 22±1.4 (3) 6.6±0.3 (3)b 19±3.2 (3) 6.8±0.1 (3)b 20±0.6 (3)
4 A3-DABK 7.3±0.1 (3)a 23±0.7 (3) 6.1±0.2 (3)b 28±5.5 (3) 6.4±0.2 (3)b 25±3 (3)
5 A4-DABK 7.1±0.1 (3)a 26±1.2 (3) 6.2±0.3 (3)b 24±6.6 (3) 6.6±0.1 (3)b 23±1 (3)
6 A5-DABK 8.1±0.2 (3) 26±1.7 (3) 6.4±0.1 (3)b 23±2.2 (3) 7.1±0.1 (3)b 19±0.5 (3)
7 A6-DABK 8.1±0.2 (3) 29±1.8 (3) 6.5±0.2 (3)b 21±3.1 (3) 7.0±0.1 (3)b 21±1 (3)
8 A7-DABK 8.0±0.1 (3) 23±1.25 (3) 6.5±0.1 (3)b 21±1.0 (3) 7.4±0.1 (3)b 19±0.6 (3)
9 A8-DABK 6.8±0.1 (3)a 19±1.67 (3) 5.8±1.0 (3)b 41±54.1 (3) 6.2±0.5 (3)b 17±5 (3)
10 K0-DABK 7.7±0.2 (3) 26±2.1 (3) 6.1±0.7 (3)b 27±19.4 (3) 6.6±0.2 (3)b 23±0.3 (3)
11 K1-DABK 8.6±0.1 (3) 34±1.6 (3) 6.5±0.3 (3)b 24.5±5.5 (3) 7.3±0.1 (3)b 21±1 (3)
12 L4-DABK 7.6±0.1 (3) 15.5±0.7 (3) 6.0±0.4 (3)b 31±14.2 (3) 6.9±0.1 (3)b 19±0.1 (3)
The IP3 productions were obtained in response to increasing concentrations of DABK and analogs in cells expressing either thewild-type or the kinin B1 mutant receptors. The pD2 values
(negative logarithm of the agonist concentration (M) that induces 50% of the maximal effect) were extracted from the concentration-response sigmoid logistic curves. The maximal
effect (Emax) was calculated in relation to the maximal effect of each peptide. Data are means±S.D. and (n) number of experiments. DABK=Arg1-Pro2-Pro3-Gly4-Phe5-Ser7-Pro7-Phe8.
a Different from DABK. Pb0.05.
b Different of respective peptide from WT receptor. Pb0.05.
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for EC50 values related to IP3 formation and calcium mobilization
(Tables 4 and 5).
3.3. Parameters for interaction of Asp712Ala mutated B1R and DABK
analogs
Parameters for interaction of DABK and its analogswith themutant
Asp712Ala were drastically modiﬁed in relation to those observed for
thewild receptor. In fact, IC50 values varied from 3 to 370 nM for bind-
ing afﬁnity (Table 3), for EC50 values from 6 to 360 nM for IP3 forma-
tion (Table 4) and from 4 to 192 nM for calcium mobilization to B1R
(Table 5). Emax values for the three parameters were not correlated
to the several amino acids residues of the analogs (Tables 3–5).
Bindings of DABK analogs to the mutated receptor were shown to
beweaker than those of the same analogs towild receptor but keeping
the same proﬁle, except for the R1 residue. The A2-, A4- and A8-DABK
analogs caused a range of binding afﬁnity (IC50 values) varying from
400 to 900 nM and from 200 to 640 nM for A5- and A7-DABK analogs.
The IC50 value for A1-DABK analog devoid of R1-DABK residue wasTable 5
Intracellular calcium mobilization in response to DABK and DABK analogs on wild-type and
Compound Analogs WT Asp
pD2 Emax pD
1 DABK 8.3±0.2 (3) 3240±241 (3) 6.7
2 A1-DABK 6.8±0.6 (3)a 1957±481 (3) 6.6
3 A2-DABK 7.5±0.2 (3)a 1650±121 (3) 6.0
4 A3-DABK 7.5±0.3 (3)a 1844±202 (3) 6.1
5 A4-DABK 7.5±0.3 (3)a 1615±173 (3) 6.0
6 A5-DABK 8.0±0.1 (3) 2899±181 (3) 6.3
7 A6-DABK 8.5±0.3 (3) 3396±291 (3) 6.5
8 A7-DABK 8.2±0.1 (3) 3060±147 (3) 6.6
9 A8-DABK 7.0±0.2 (3)a 1991±233 (3) 5.9
10 K0-DABK 8.0±0.4 (3) 2638±338 (3) 6.4
11 K1-DABK 8.7±0.3 (3)a 3057±266 (3) 6.3
12 L4-DABK 6.5±0.4 (3)a 1160±218 (3) 5.9
The intracellular calcium ([Ca2+]i) changes were obtained in response to increasing concentration
tors. The pD2 values (negative logarithm of the agonist concentration (M) that induces 50% of the
The maximal effect (Emax) was calculated in relation to the effect of each peptide. Data are mean
a Different from DABK. Pb0.05.
b Different of respective peptide from WT receptor. Pb0.05.170 nM. As for wild receptor, a similar proportion of values were
found for EC50 values for IP3 formation and calcium mobilization
(Tables 4 and 5).3.4. Parameters for interaction of Cys100Ser mutated B1R and DABK
analogs
Absence of the second disulﬁde bond in Cys100Ser mutated B1R
caused a deleterious effect on the binding afﬁnity of A2-, A3-, A4-
and especially of A8-DABK (Table 3). The proﬁle for changes was
quite similar to that produced by Asp712Ala mutant receptor. How-
ever the increases in EC50 values were lower than those observed
with wild receptor. Effects on IP3 formation and calcium mobilization
followed a same proﬁle (Tables 4 and 5). Thus it is plausible to asso-
ciate the twomutations to a same effect on the receptor leading to the
modiﬁcation of the extracellular site structure. A fact remaining to be
explained is why the binding of F8-DABK analog was so reduced upon
receptor Cys650 mutation by the same rate that observed for the
Asp712Ala mutant, (Table 3).mutant kinin B1 receptors.
712Ala Cys100Ser
[Ca2+]i
2 Emax pD2 Emax
±0.1 (3)b 2307±183 (3) 7.0±0.3 (3)b 2092±292 (3)
±0.1 (3)b 2087±206 (3) 6.9±0.1 (3)b 1956±65 (3)
±0.3 (3)b 2342±1269 (3) 6.4±0.4 (3)b 2486±630 (3)
±0.3 (3)b 2767±724 (3) 6.3±0.7 (3)b 2578±1122 (3)
±0.3 (3)b 2123±955 (3) 6.6±0.2 (3)b 2120±312 (3)
±0.2 (3)b 1793±417(3) 7.4±0.2 (3)b 1977±167 (3)
±0.2 (3)b 2302±359 (3) 7.1±0.1 (3)b 1994±64 (3)
±0.3 (3)b 2320±362 (3) 7.1±0.1 (3)b 2013±79 (3)
±0.4 (3)b 2393±558 (3) 6.4±0.5 (3)b 2528±775 (3)
±0.3 (3)b 2490±547 (3) 7.1±0.2 (3)b 2084±179 (3)
±0.2 (3)b 2555±475 (3) 7.2±0.1 (3)b 2069±121 (3)
±0.5 (3)b 2608±898 (3) 6.5±0.1 (3)b 2059±168(3)
s of DABK and analogs in cells expressing either the wild-type or the kinin B1 mutant recep-
maximal response) were extracted from the concentration-response sigmoid logistic curves.
s±S.D. and (n) number of experiments. DABK=Arg1-Pro2-Pro3-Gly4-Phe5-Ser7-Pro7-Phe8.
Fig. 4. Association of des-Arg9-Bradykinin with kinin B1 receptor. An ampliﬁed version
of the structure showing the receptor the seven transmembrane-helix bundle in dark
blue and the conserved Cys315–Cys470 disulﬁde bond in gold. The receptor extracellular
site is shown in the top of the ﬁgure consisting of Nt and EC3 segments (light blue), the
Cys650–Cys100 disulﬁde bond (gold) and the residue insertion (green). The peptide
inserted into a postulated binding site with a horseshoe conﬁguration is shown in ma-
genta, the peptide C-carboxylate and receptor helix V Arg508 and helix III Lys323 and the
peptide N-terminal Arg1 side-chain and the receptor extracellular site Asp712.
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4.1. Structural requirements for DABK binding to kinin B1 receptor
Present study shows that the residues R1, P2, P3, G4 and F8 play
major roles in DABK binding to the B1R. Previous report on the biologic
activity of these peptide analogs over the same receptor is in general
agreement with these results [21]. R1 certainly is the main binding-
involved residue, at least at the Nt side of the peptide by acting
through its positive charge which can be perfectly replaced by Lys
(Table 3) without loss of binding afﬁnity. In the extreme ends of
DABK, other complex mechanisms than those dependent on the type
of residue side-chain, ought to be considered in order to explain the
effects observed.
In the Ct side, the DABK F8 side-chain seems to be decisive for
peptide binding and activity-triggering as denoted by the values in
Tables 2–5 but it might also be accessory considering the importance
of the special binding of the Ct carboxylate with the helix III Lys323
[10] and helix V Arg508 [11] residues at the external half of receptor
7TM central cavity. This association makes DABK the full-agonist of
B1R receptor whereas kinin B2 receptor is able to bind BK since it con-
tains an additional locus located one position ahead of its structure to
bind the residue R9 of this peptide.
Binding of Nt segment of DABK to kinin B1R still seems to display a
dependence on residues that are occupying positions-2, -1 and -0,
preceding the positions 1–8 of the peptide itself. For instance, the
presence of K0, as in kallidins, impairs the binding and activity of rat
or mouse B1R a little but considerably affects the same properties of
these receptors coming from other species as man, rabbit, cow and
others. No explanation has been available yet in order to explain
this difference [22].
4.2. Factors regulating DABK binding to the kinin B1 receptor
A speciﬁc salt bridge between the DABK R1 side-chain and B1R
Asp712 seems to be the basic component for a wild-type binding
mode involving peptide and receptor [12]. As an indication of this con-
dition, IC50 values of 3 nM or 152 nM are found for complexes be-
tween the wild-type receptor and DABK or A1-DABK in which the
bond is present or not, respectively (ﬁrst and second lines of the ﬁrst
IC50 data column in Table 3). For complexes betweenwild-type recep-
tor and A2-, A3- and A4-DABK analogs (Table 3, ﬁrst data column), the
IC50 values are between 3 and 152 nM, thus denoting that the binding
was weakened by effects due to local mutation of P2, P3 and G4 to Ala.
For DABK with Ala at positions 5–7, the binding was wild-like but de-
creased again for the A8-DABK analog thus indicating a special binding
mode for the peptide F8 residue.
On the other side, if the speciﬁc salt bridge is eliminated upon
an Asp712Ala mutation in the B1R, other event leading to weakening
of the peptide binding seems to take place. This is indicated by IC50
values shown in the middle IC50 data column (Table 3) that are
found following the trend of variation of the corresponding data in
the ﬁrst column but at a higher level of IC50 values. The sole exception
for this correlation was the binding of A1-DABK analog to mutated re-
ceptor for which the IC50 value of 172 nM was comparable to the IC50
value of 152 nM observed for the binding of the same analog to wild
receptor. Thus, the logical conclusion hypothesized from this ﬁnding,
was that the presence of free R1 residue in DABK analogs is responsi-
ble by a systematic weakening of the interaction of these compounds
with receptor.
It is opportune at this point to analyze, how the loss of the second
extracellular bond Cys100–Cys650 might have affected the bindingmode
of DABK and analogs to Cys100Ser-mutated B1 receptor (Table 3). As de-
scribed, the proﬁle of variation for effects obtained with the Asp712 and
Cys100 mutations seems to be similar. However, differences between
IC50 values obtained with analogs and mutated receptors in relation tothe corresponding values with analogs and wild receptors are higher
for Asp712 mutation than for Cys100 mutation.
This aspect cannot be related to the factors considered for Asp712-
mutated receptors since speciﬁc salt-bridge and free-peptide-Arg1
conditions (except for A1-DABK bindings) are equally present in com-
plexes involving DABK and analogs, Cys100-mutated and wild recep-
tors. Thus, a distinct effect on the extracellular site produced by loss
of the disulﬁde bond remains to be considered being it transmitted
to other regions of the receptor thereby affecting the whole peptide
binding. This transmission might follow a pathway formed by recep-
tor sub-loci with speciﬁcity for binding DABK residue positions 2, 3, 4
and 8 for which mutation to Ala gave rise to receptor binding with
higher IC50 values (Table 3).
The large effect on DABK binding to B1R due to exchange of the
peptide F8 residue remains only partially explained. It is present in
both Asp712- and Cys100-mutated receptors and starts as a disarrange-
ment of the extracellular site structure at the other side of the receptor
7TM bundle. It is possible that a general binding of the DABK Ct, in-
volving the F8 residue and the carboxylate group to receptor locus
ﬂanked by helices III, V and VI, could work like an anchor holding
the peptide inside the binding locus, probably following a bimodal
mechanism of binding to be arisen along the next sections.4.3. DABK binding site in B1 receptor
Thus, three major connections have now been recognized in the
DABK-B1R complex: (a) a speciﬁc salt-bridge (Table 3) between peptide
R1 residue and receptor extracellular site Asp712; (b) a salt-bridge be-
tween the receptor Ct carboxylate and receptor helix III Lys323 [10]
and helix V Arg508 [11]; and (c) aromatic-ring interactions involving
the DABK F8 residue and aromatic residues placed in the middle of re-
ceptor helix VI (Tyr621, His622, Phe623 and Phe624), [12].
The present picture allows us to point out to a very plausible
condition in which the molecule of bound-agonist is shown as a
U-shaped ﬁgure (Fig. 4). The ﬁrst arm of this ﬁgure is linked to the re-
ceptor extracellular site via R1-Asp712 bridge. The interaction of the
44 E.S. Rodrigues et al. / Regulatory Peptides 181 (2013) 37–44second arm consists of two components, the ﬁrst one represented by
the binding of the Ct peptide residue F8 to a very conserved receptor
aromatic-ring cluster and the second one by the binding of the pep-
tide Ct carboxylate to the positive side-chains of helix III Lys323 [10]
and helix V Arg508 [11]. The apparently non-bonded peptide F5,
S6 and P7 residues is distributed over the bend of the horseshoe, a
condition that is consistent since these residues are not important
for peptide activity (Table 2), binding (Table 3) and participation in
post-activation events as IP3 formation and calcium mobilization
(Tables 4 and 5).
4.4. Concluding remarks
In short, experimental data of the current work could emphasize
some remarkable points about the interaction mode of DABK to B1R.
(1) The residues of F5, H6 and P7, devoid of importance for biolog-
ical activity, agonist binding and post-activation events, are in
the middle of the peptide sequence.
(2) A model of B1R built from chemokine CXCR4 receptor, shows
that, in order to fulﬁll all interactions suggested by previous
mutagenesis studies, DABK has to exhibit a U-shaped conﬁgu-
ration so that its extremes are bound to two distinct but close
regions of the receptor (Fig. 4) and its middle bend is probably
in a non-bonded condition.
(3) This scheme indicates that the interaction of DABK with B1R is
bimodal. The Nt extreme of the peptide binds at the extracellu-
lar site of receptor whereas the Ct extreme binds at a locus
ﬂanked by the extracellular halves of helices III, V and VI.
(4) Modiﬁcations carried out on the extracellular site of B1R as
Asp712Ala and Cys100Ser mutations, reduced the binding of
DABK analogs to these mutated receptors and the activity elic-
ited by this binding, by a process that followed the same proﬁle
previously observed with binding of DABK analogs to wild re-
ceptor. That is, for both wild and mutated receptors structural
modiﬁcations were more deleterious for binding of peptide
analogs when residues were changed at both extremes than
at the middle of the peptide sequences. This fact would require
that Asp712Ala and Cys100Ser mutations should induce equal-
ly modiﬁcations on the other side of the receptor structure,
namely at the subsite for binding DABK Ct F8 residue and
C-carboxylate as widely shown in Tables 3–5. In general, the
symmetrical distribution of modiﬁcations induced on B1R struc-
ture would have a unique development: structure of receptor
may be modiﬁed by residue mutations but the U-shaped conﬁg-
uration of DABK forming an overall complex with the receptor is
kept unchanged.
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